Oxytocin is under clinical development by OT4B and currently in Phase III for Prader-Willi Syndrome (PWS). According to GlobalData, Phase III drugs for Prader-Willi Syndrome (PWS) have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Oxytocin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Oxytocin overview

Oxytocin is under development for the treatment of Prader-Willi syndrome in pediatrics, children and adults. It is administered through nasal route. The drug candidate acts by targeting oxytocin receptor.

OT4B overview

OT4B is a biomedical company developing novel therapeutic solutions for the treatment of Prader-Willi syndrome. Its pipeline comprises Phase I and Phase II clinical studies, which focus on evaluating the administration of intranasal oxytocin in infants with Prader-Willi syndrome. The company is also advancing pipeline programs for evaluating the effect of oxytocin in Prader-Willi syndrome in phase II and III clinical studies for children and adults. OT4B advances its clinical programs in collaboration with Toulouse University Hospital. The company is funded by the La French Tech, bpifrance, and Galpaco. OT4B is headquartered in Toulouse, Midi Pyrenees, France.

For a complete picture of Oxytocin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 15 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.